Recent article by Chessmaster was awesome. I might add that it was also refreshing. If we are to talk about the same things over & over, he offers many positives to draw from. Maybe not enough drama & " poor pitiful me" rhetoric for some.
All the possibilities mentioned create an exciting environment for CYDY shareholders. Just as easy to think the best.
Saw where Lenzilumab seems to be gaining favor in the UK. This should bode well for Leronlimab, as there seems to be a growing interest in therapeutics vs the vaccine only approach.
Still much work to be done. I will start worrying when there is no work to be done.